Background. LF 15-0195 (LF), a novel analogue of 15-deoxyspergualin (DSG), inhibits maturation of dendritic cells (DC). Anti-CD45RB is a monoclonal antibody (mAb) that blocks activation of T-helper (Th) 1 cells and generates T-regulatory cells. This study addressed whether these two reagents act synergistically to inducing tolerance, and investigated associated cellular mechanisms.
Agents that temporarily deplete T cells such as anti-CD45RB monoclonal antibodies (mAb), when administered before organ transplantation, have been shown to induce transplant tolerance (1, 2) . In addition, agents such as 15-deoxyspergualin (DSG) that inhibit antigen-presenting cell (APC) function are also capable of inducing tolerance (3) . In the context of transplantation, the antigen-presentation step of T-cell activation determines whether the T cell will reject the graft, ignore the graft, or inhibit other T cells from attacking the graft. The T cell that blocks other T cells from attacking the graft is termed a T-regulatory (Treg) cell. By modulating the recipient's APC, it may be possible to cause expansion of graft protecting Treg cells without suppressing immune responses to other antigens.
Dendritic cells (DC) are the most potent APC that are capable of activating naive T cells (4) . DC in the periphery capture and process antigens and, on activation, migrate to lymphoid organs where they express co-stimulatory molecules and secrete cytokines to initiate T-cell responses. DC are believed to play a critical role in the process of both central and peripheral tolerance (5) . Although DC in the thymus are responsible for negative selection (6) , some investigators have reported that immature DC in the periphery cause deletion of autoreactive cells (7, 8) or lead to generation of self-reactive Treg cells, or both (9) . The subsets of DC responsible for tolerance induction are not fully characterized yet and are different with respect to anatomic location and function. However, DC with an immature phenotype (low expression of major histocompatibility complex [MHC] class II, CD40, CD80, CD86, interleukin [IL]-12) are generally considered to possess tolerance-promoting properties and are termed tolerogenic DC (Tol-DC) (10) . The role of Tol-DC in transplantation tolerance has been demonstrated in several animal models. For example, prolonged cardiac allograft survival was achieved in both mice and rats when donor strain immature DC were administered to the recipient before transplantation (11) (12) (13) . The inherent tolerogenicity of liver allografts has been attributed, in part, to the large number of donor Tol-DC residing within the transplanted liver (14, 15) .
In light of the potential for Tol-DC to induce tolerance, the authors targeted DC function in transplant recipients using LF 15-0195 (LF), an analogue of DSG. The authors have previously shown that LF monotherapy (20-day course) induces permanent allograft tolerance (16) ; however, 20% of recipients died because of LF-induced toxicity. Because of the importance of the DC-T-cell interaction during graft rejection, the authors tested whether concurrent modulation of T-cell function by means of anti-CD45RB mAb treatment along with a safe, short-course, low-dose treatment of LF could result in enhanced graft survival.
MATERIALS AND METHODS

Animals and Tolerance Induction
Male C57BL/6, BALB/c, and C3H mice were purchased from Jackson Laboratories (Bar Harbour, Maine) and were used as donors, recipients, and third-party controls, respectively. Eight mice (BALB/c) of each group were treated with anti-CD45RB mAb 3 mg/kg/day, day Ϫ1 to 7 intravenously (group 1); LF 2 mg/kg/day, day 0 to 7 subcutaneously (group 2); and combination LF plus mAb using the same regimen as in groups 1 and 2 (group 3). Untreated allograft recipients were used as controls.
Heterotopic Cardiac Transplantation
Treated and untreated BALB/c mice were subjected to allogeneic cardiac transplantation using C57BL/6 donors. Direct abdominal palpation was used for assessing graft viability. Heterotopic heart transplantation was performed according to routine procedure in the authors' laboratory (17) . Rejection of graft was judged by the cessation of heartbeat. Recipients with grafts surviving longer than 100 days were defined as tolerant and were used for in vitro experiments.
Generation of Bone Marrow-Derived Dendritic Cells
The procedure used in the authors' laboratory to generate DC was described elsewhere (18) . In brief, bone marrow cells were flushed from the femurs and tibias of tolerant, rejective, naive mice, and washed and cultured at a concentration of 2ϫ10 6 cells per well in 24-well plates (Corning, Corning, NY) in 2 mL RPMI 1640 (GIBCO Life Technologies, Burlington, Ontario, Canada) supplemented with 10% fetal calf serum (FCS) (GIBCO), 100 U/mL of penicillin, 100 g/mL of streptomycin, 50 M of 2-mercaptoethanol (GIBCO), 10 ng/mL of recombinant murine granulocyte-macrophage colony-stimulating factor (Peprotech, Rocky Hill, NJ), and 10 ng/mL of IL-4 (Peprotech). Nonadherant cells were removed after 48 hr of culture, and fresh medium was added every 48 hr. DC were used for in vitro experiments after 9 days of culture.
Isolation of Splenic DC from Allograft Recipients
Splenic mononuclear cells were isolated from recipient spleens by gradient centrifugation over Ficoll-Paque (Amersham, Pharmacia Biotech, Uppsala, Sweden) and labeled with anti-mouse CD11c mAb conjugated MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Subsequently, the CD11c ϩ cells were positively separated by a magnetic column. The CD11c ϩ DC were used directly for further experiments.
Flow Cytometry
Phenotypic analysis of isolated or cultured DC was performed on a FACScan (Becton Dickinson, San Jose, CA). The following fluorescein isothiocyanate-or phycoerythrin-conjugated anti-mouse mAb were purchased from BD PharMingen (San Diego, CA): I-A d , CD11c, CD40, CD86, and IL-12. IL-12 expression was assessed by intracellular staining using a cell permeabilization kit (Cedarlane Laboratories, Hornby, Ontario, Canada). All flow cytometric analyses were performed using appropriate isotype controls (Cedarlane).
Mixed Leukocyte Reaction
Splenic DC isolated from tolerant or rejecting recipients (BALB/c) were irradiated at 3,000 rad. Varying numbers of DC were seeded in triplicate in a flat-bottomed 96-well plate (Corning) for use as stimulator cells. T cells were prepared from spleens and isolated by T-cell enrichment columns. T cells (1-5ϫ10 5 cells/ well) from C57BL/6 mice were added to the DC cultures, with the final mixed leukocyte reaction (MLR) reaction taking place in 200 L of RPMI 1640 (GIBCO) supplemented with 10% FCS (GIBCO), 100 U/mL of penicillin (GIBCO), and 100 g/mL of streptomycin (GIBCO). Cells were cultured for 3 days and pulsed with 1 Ci of 3 H-thymidine (Amersham Pharmacia Biotech) for the last 16 hr of culture. Cells were harvested onto glass fiber filters, and the radioactivity incorporated was quantitated using a Wallac Betaplate liquid scintillation counter (Beckman, Fullerton, CA). Results were expressed as the mean counts per minute of triplicate culturesϮSEM.
T-Cell Proliferation Assays
To test co-stimulatory function of DC, purified BALB/c CD4 ϩ T cells (1ϫ10 6 To assess the ability of DC to stimulate antigen-specific T-cell responses, lymph node T cells were isolated from BALB/c mice immunized with pigeon cytochrome c peptide (PCC) 81-104. PCCspecific T cells (2ϫ10 5 cells/well) were incubated with splenic DC (5ϫ10 4 cells/well) isolated from tolerant, rejective, or naive mice in the presence of PCC 81-104 peptide (1-100 g/mL) for 3 days. T-cell proliferation was assessed by 3 H-thymidine uptake assay as described above.
Enzyme-Linked Immunosorbent Assay
Bone marrow-derived DC (10 5 , BALB/C origin) were cultured with the C57B/L6 T cells (1ϫ10 6 ) for 48 hr. The supernatants were harvested and assessed for interferon (IFN)-␥ and IL-4 by enzymelinked immunosorbent assay (ELISA). Cytokine-specific ELISA (Endogen, Rockford, IL) was used for detecting protein concentrations in culture supernatants according to the manufacturer's instructions using a Benchmark Microplate Reader (Bio-Rad Laboratories, Hercules, CA). The amounts of IFN-␥ and IL-4 produced by the T cells were determined from standard curves generated with recombinant murine IFN-␥ and IL-4 (Endogen).
RESULTS
Combination of Anti-CD45RB mAb and LF Act
Synergistically to Induce Tolerance Untreated C57BL/6 cardiac allografts were rapidly rejected, with median survival of 7.5 days. Monotherapy with mAb or LF significantly prolonged C57BL/6 allograft survival to 42 and 40 days, respectively, but both agents alone failed to induce tolerance. In contrast, a short course of LF plus mAb resulted in indefinite survival (Ͼ200 days) ( Table  1 ). The long-term survivors accepted skin grafts from the donor strain permanently (Ͼ100 days) and rejected thirdparty skin grafts (11 days, data not shown). These data indicate that LF and mAb act synergistically to induce donorspecific tolerance.
Pathologic examination at necropsy showed that allografts from untreated recipients, and those treated with LF or mAb alone, developed moderate to severe cellular and vascular rejection, characterized by massive cell infiltration, vasculitis, hemorrhage, infarction, and thrombosis ( Fig. 1A-C) . In contrast, allografts from long-term survivors (Ͼ200 days) treated with a short course of LF plus mAb showed normal histopathology of heart grafts and no evidence of chronic rejection (Fig. 1D) . Therefore, targeting both T cells and APC by treatment with anti-CD45RB mAb and LF, respectively, is an effective and practical strategy for inducing tolerance.
Bone Marrow DC Isolated from Tolerant Recipients Show Immature Phenotype and Promote T-Helper Cell Type 2 Polarization
Because a short term (8-to 9-day) treatment with the combination of anti-CD45RB mAb and LF resulted in indefinite tolerance to allografts (Table 1) , the authors postulated that in addition to T-cell-mediated tolerance, tolerogenic DC were simultaneously generated in tolerant recipients. Indeed, the authors have previously reported that splenic DC isolated from tolerant recipients expressed tolerogenic phenotypes and function (16) . The authors investigated whether bone marrow-derived DC possess tolerogenic properties. Bone marrow progenitors were isolated from tolerant and age-matched naive mice. After 9 days of in vitro culture, DC generated from bone marrow of control mice and tolerant mice expressed similar levels of CD11c and DEC-205, indicating that the authors' protocol for generating DC was efficient. DC generated from naive mice showed high expression of MHC class II and the co-stimulatory molecules CD40 and CD86. In contrast, DC cultured from bone marrow of tolerant recipients showed lower expression of MHC class II and CD40 (Fig. 2A) . In addition, DC generated from bone marrow of tolerant mice did not produce IL-12 protein or transcript as detected by flow cytometry and reverse-transcriptase polymerase chain reaction (data not shown). To investigate whether the lack of IL-12 expression on the DC altered ability to polarize T-helper (Th) cell differentiation, cytokines produced by allogeneic T cells responding to these DC were assessed by ELISA. In agreement with the potential tolerogenic properties of these cells, when DC generated from the bone marrow of tolerant recipients were used as stimulators in MLR, the responding T cells acquired a Th2 cytokine profile as evidenced by increased expression of IL-4 and decreased expression of IFN-␥ (Fig. 2B) .
Splenic DC Isolated from Tolerant Recipients Inhibit MLR and Antigen-Specific T-Cell Response
Recipient DC may play a role in the induction of transplantation tolerance by presenting donor antigens to T cells and causing their differentiation to Treg cells (19) . For this to occur, the recipient DC must be immature or possess Tol-DC function. The data in Figure 2 (A) showed that bone marrowderived DC isolated from tolerant recipients exhibited immature phenotype. Because a major proportion of bone marrowderived DC are found in the spleen, the authors assessed the function of splenic DC for rejecting and tolerant recipients for their ability to stimulate allogeneic T-cell responses. In an MLR assay, DC isolated from tolerant recipients failed to stimulate allogeneic T-cell responses (Fig. 3A) .
To assess whether Tol-DC are poor antigen presenters to T cells, an antigen-specific recall experiment was performed. Lymph node T cells were isolated from BALB/c mice immunized with PCC 81-104 . PCC-specific T-cell responses were assessed in the presence of splenic DC isolated from normal mice and from rejecting and tolerant recipients. In the presence of PCC 81-104 peptide, rejective DC evoked a vigorous antigen-specific T-cell proliferative response, whereas DC isolated from tolerant recipients failed to elicit an antigenspecific T-cell response (Fig. 3B) . These data support the concept that tolerant recipients possess increased numbers of Tol-DC.
Splenic DC Isolated from Tolerant Recipients Fail to Provide Co-stimulatory Signals to T Cells
T-cell activation needs both antigenic stimuli from MHC-T-cell receptor (signal 1) and co-stimulatory signals (signal 2). Without co-stimulation, T cells become anergic, undergo apoptosis, or differentiate into Treg cells. To assess whether splenic DC from tolerant mice provide weaker co-stimulatory signals than DC from rejecting and control mice, an in vitro model of co-stimulation was used. Purified CD4 ϩ T cells from naive BALB/c mice were stimulated with soluble anti-CD3 mAb as a source of signal 1. DC from the three groups were added as a source of signal 2. DC isolated from rejective recipients showed the strongest co-stimulatory activity for anti-CD3-induced T-cell proliferation (Fig. 4) . DC isolated from naive mice provided weaker co-stimulation, and DC from tolerant mice actually inhibited proliferation. These data suggest that tolerance induction causes a functional alteration in DC co-stimulatory activity that is present even 100 days after transplantation.
DISCUSSION
In this study, the authors have demonstrated that the combination treatment of recipients with LF and anti-CD45RB mAb resulted in the induction of synergistic tolerance, whereas nontoxic doses of monotherapy with either reagent could not induce tolerance in the C57B/L6 to BALB/c heart transplantation model (16, 17) . This combination protocol is promising from a clinical perspective because the immune-modulating agents were administered for only 8 to 9 days. In agreement with the authors' findings, other studies have successfully prolonged graft survival by simultaneously blocking DC maturation and T-cell function (20 -24) .
LF is a novel antirejection drug developed through the chemical modification of DSG to increase immunosuppressive activity and to decrease toxicity. As compared with conventional immunosuppressants, the uniqueness of LF and DSG as antirejection drugs is that both block rejection responses through inhibition of APC function (3). However, the mechanism of action may be different between DSG and LF. DSG inhibits hsc 70 translocation to the nucleus, which contributes to inhibition of nuclear factor (NF)-B (25) . In contrast, LF directly binds IB kinase and blocks phosphorylation of IB, this in turn, does not allow for release and subsequent nuclear translocation of NF-B (J. Yang, Ph.D., et al., unpublished data, 2003).
Antigen presentation is primarily performed by DC, which possess both a stimulatory and inhibitory role in T-cell activation, depending in part on whether they are mature or immature. In previous studies, the authors have also demonstrated that tolerance induced by LF is associated with generation of tolerogenic DC 16. The term Tol-DC defines an immature DC population that possesses low levels of costimulatory molecules and is a poor stimulator of MLR. The fact that addition of DC from tolerant recipients actually inhibited T-cell proliferation induced by anti-CD3 mAb (Fig.  4) suggested to the authors that the Tol-DC were actively inhibiting the T cells, either directly by means of the coinhibitory signals such as immunoglobulin-like transcript (ILT)-3 and ILT-4 (19), or indirectly by means of Tol-DC generating Treg cells (26) , which in turn inhibits proliferation of T cells through inhibitory factors such as transforming growth factor-␤ and IL-10.
Interestingly and unexpectedly, the DC progenitors in the bone marrow were able to maintain their tolerogenic phenotype after 9 days of in vitro culture. Shurin et al. (27) reported that bone marrow progenitors derived from tolerogenic situations such as tumor-bearing mice possess a predisposition toward developing into immature cells (CD40 low , CD86 low ) similar to the DC observed in this study, even though the cells were allowed to differentiate in vitro in the absence of immunosuppressive agents. This concept of progenitor "programming" by the tolerogenic environment requires further study.
Treg cells are believed to be critical for the induction of donor-specific tolerance because of their ability to suppress activated T cells in an antigen-specific manner. For Treg to be generated and expanded, an antigen-specific signal needs to be provided by an APC. Because APC also activate conventional T cells that cause graft rejection, it is essential that only the APC that stimulate Treg cells are activated in the recipient. Tol-DC possess an immature phenotype and inhibit proliferation of conventional T cells but activate and expand Treg cells. Because LF induces Tol-DC formation, administration of LF should induce Treg cells. In agreement with this, it has recently been demonstrated by Chiffoleau et al. (28) that LF blocks graft rejection in a rat cardiac allograft model through generation of Treg cells that were capable of adoptively transferring tolerance. The work by Chiffoleau et al. indicated that Treg cell generation was dependent on donor-derived DC because depleting donor APC resulted in an incapability to generate Treg cells (28) . In contrast, the authors' previous study demonstrated that recipient-derived Tol-DC contribute to the generation of Treg cells (26) . It is possible that both the donor and recipient DC play important roles in tolerance induction, depending on the transplant model used. In the current study, the authors further demonstrated that DC from tolerant recipients could neither evoke antigen-specific T-cell responses nor provide co-stimulation to T cells. Furthermore, these DC possessed low phenotypic expression of co-stimulatory molecules. On the basis of these properties, the authors conclude that an expanded Tol-DC population is present in tolerant mice and contributes to maintenance of graft survival. 
